RESEARCH ARTICLE
Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer Melissa Chan1,2, Martin C. Chang3,4, Rosa González5, Belinda Lategan3,4, Elvira del Barco6, Francisco Vera-Badillo1,2, Paula Quesada6, Robyn Goldstein1, Ignacio Cruz7, Alberto Ocana8, Juan J. Cruz6, Eitan Amir1,2* 1 Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada, 2 Department of Medicine, University of Toronto, Toronto, ON, Canada, 3 Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada, 4 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, 5 Escuela de Enfermeria, Universidad de Salamanca, Salamanca, Spain, 6 Medical Oncology Department, Salamanca University Hospital, Salamanca, Spain, 7 Servicio de Cardiología, Complejo Hospitalario de Salamanca, Salamanca, Spain, 8 Medical Oncology Department and Translational Research Unit, Albacete University Hospital, Albacete, Spain * [email protected]
OPEN ACCESS Citation: Chan M, Chang MC, González R, Lategan B, del Barco E, Vera-Badillo F, et al. (2015) Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer. PLoS ONE 10(7): e0132449. doi:10.1371/journal. pone.0132449 Editor: Aamir Ahmad, Wayne State University School of Medicine, UNITED STATES Received: April 24, 2015 Accepted: June 15, 2015 Published: July 10, 2015 Copyright: © 2015 Chan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability Statement: Due to ethical restrictions, data are available upon request. Interested researchers may submit requests for sensitive data to the Corresponding Author at eitan. [email protected] Funding: The authors received no specific funding for this work. Competing Interests: The authors have declared that no competing interests exist.
Abstract Purpose To describe the clinical features and outcomes of estrogen receptor negative (ER-) and progesterone receptor positive (PgR+) breast cancer.
Methods We retrospectively reviewed a well-characterized database of sequential patients diagnosed with early stage invasive breast carcinoma. Outcomes of interest were time to relapse (TTR) and overall survival (OS). Multivariable Cox proportional hazards analysis was conducted to assess the association of ER-/PgR+ with TTR and OS in comparison to ER+ and to ER- and PgR negative (ER-/PgR-) tumors irrespective of HER2 status. ER and PgR expression was conservatively defined as 10% or greater staining of cancer cells.
Results 815 patients were followed for a median of 40.5 months; 56 patients (7%) had ER-/PgR+, 624 (77%) had ER+ and 136 (17%) had ER-/PgR- phenotypes. Compared with ER+ tumors, ER-/PgR+ tumors were associated with younger age (50 versus 59 years, p=0.03), high grade (50% versus 24%, p
Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer Melissa Chan1,2, Martin C. Chang3,4, Rosa González5, Belinda Lategan3,4, Elvira del Barco6, Francisco Vera-Badillo1,2, Paula Quesada6, Robyn Goldstein1, Ignacio Cruz7, Alberto Ocana8, Juan J. Cruz6, Eitan Amir1,2* 1 Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada, 2 Department of Medicine, University of Toronto, Toronto, ON, Canada, 3 Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada, 4 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, 5 Escuela de Enfermeria, Universidad de Salamanca, Salamanca, Spain, 6 Medical Oncology Department, Salamanca University Hospital, Salamanca, Spain, 7 Servicio de Cardiología, Complejo Hospitalario de Salamanca, Salamanca, Spain, 8 Medical Oncology Department and Translational Research Unit, Albacete University Hospital, Albacete, Spain * [email protected]
OPEN ACCESS Citation: Chan M, Chang MC, González R, Lategan B, del Barco E, Vera-Badillo F, et al. (2015) Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer. PLoS ONE 10(7): e0132449. doi:10.1371/journal. pone.0132449 Editor: Aamir Ahmad, Wayne State University School of Medicine, UNITED STATES Received: April 24, 2015 Accepted: June 15, 2015 Published: July 10, 2015 Copyright: © 2015 Chan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability Statement: Due to ethical restrictions, data are available upon request. Interested researchers may submit requests for sensitive data to the Corresponding Author at eitan. [email protected] Funding: The authors received no specific funding for this work. Competing Interests: The authors have declared that no competing interests exist.
Abstract Purpose To describe the clinical features and outcomes of estrogen receptor negative (ER-) and progesterone receptor positive (PgR+) breast cancer.
Methods We retrospectively reviewed a well-characterized database of sequential patients diagnosed with early stage invasive breast carcinoma. Outcomes of interest were time to relapse (TTR) and overall survival (OS). Multivariable Cox proportional hazards analysis was conducted to assess the association of ER-/PgR+ with TTR and OS in comparison to ER+ and to ER- and PgR negative (ER-/PgR-) tumors irrespective of HER2 status. ER and PgR expression was conservatively defined as 10% or greater staining of cancer cells.
Results 815 patients were followed for a median of 40.5 months; 56 patients (7%) had ER-/PgR+, 624 (77%) had ER+ and 136 (17%) had ER-/PgR- phenotypes. Compared with ER+ tumors, ER-/PgR+ tumors were associated with younger age (50 versus 59 years, p=0.03), high grade (50% versus 24%, p
